Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI)
- PMID: 3358767
- DOI: 10.1016/s0006-291x(88)80729-0
Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI)
Abstract
Codeine O-demethylation to its active moiety morphine was investigated in human liver microsomes from 1 poor and 5 extensive metabolizer subjects (debrisoquine-type of oxidation polymorphism). Apparent Km of the reaction in one extensive metabolizer's microsomes was 149 microM and Vmax 17.6 nmol X mg P-1 X hour-1 versus greater than 1 mM and 1.6 nmol X mg P-1 X hour-1 respectively in one poor metabolizer. In vitro morphine production was competitively inhibited by quinidine (Ki 15 nM), the selective inhibitor of cytochrome P-450 dbl/bufI. There was also an excellent correlation between dextromethorphan O-demethylation, a prototype reaction for cytochrome P-450 dbl/bufI activity, and codeine O-demethylation. These data allow to conclude that codeine bioactivation to morphine is dependent on the polymorphic monooxygenase known as cytochrome db1/bufI.
Similar articles
-
Impact of environmental and genetic factors on codeine analgesia.Eur J Clin Pharmacol. 1991;41(1):23-6. doi: 10.1007/BF00280101. Eur J Clin Pharmacol. 1991. PMID: 1782973 Clinical Trial.
-
In vitro forecasting of drugs that may interfere with codeine bioactivation.Eur J Drug Metab Pharmacokinet. 1992 Apr-Jun;17(2):115-20. doi: 10.1007/BF03188779. Eur J Drug Metab Pharmacokinet. 1992. PMID: 1425809
-
Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P-450 db1 activity.Clin Pharmacol Ther. 1989 Jan;45(1):34-40. doi: 10.1038/clpt.1989.6. Clin Pharmacol Ther. 1989. PMID: 2910636
-
The pharmacogenetics of codeine hypoalgesia.Pharmacogenetics. 1995 Dec;5(6):335-46. doi: 10.1097/00008571-199512000-00001. Pharmacogenetics. 1995. PMID: 8845855 Review.
-
Pharmacogenetics of drug oxidation via cytochrome P450 (CYP) in the populations of Denmark, Faroe Islands and Greenland.Drug Metab Pers Ther. 2015 Sep;30(3):147-63. doi: 10.1515/dmdi-2014-0029. Drug Metab Pers Ther. 2015. PMID: 25719307 Review.
Cited by
-
Clinical significance of the sparteine/debrisoquine oxidation polymorphism.Eur J Clin Pharmacol. 1989;36(6):537-47. doi: 10.1007/BF00637732. Eur J Clin Pharmacol. 1989. PMID: 2570698
-
Effect of methamphetamine on the pharmacokinetics of dextromethorphan and midazolam in rats.Eur J Drug Metab Pharmacokinet. 2005 Jul-Sep;30(3):195-201. doi: 10.1007/BF03190620. Eur J Drug Metab Pharmacokinet. 2005. PMID: 16250257
-
Evidence for a role of cytochrome P450 2D6 and 3A4 in ethylmorphine metabolism.Br J Clin Pharmacol. 1995 Jan;39(1):77-80. doi: 10.1111/j.1365-2125.1995.tb04413.x. Br J Clin Pharmacol. 1995. PMID: 7756104 Free PMC article.
-
Prodrugs for the improvement of drug absorption via different routes of administration.Eur J Drug Metab Pharmacokinet. 1990 Apr-Jun;15(2):143-53. doi: 10.1007/BF03190197. Eur J Drug Metab Pharmacokinet. 1990. PMID: 2200683 Review.
-
Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.Clin Pharmacokinet. 2009;48(12):761-804. doi: 10.2165/11318070-000000000-00000. Clin Pharmacokinet. 2009. PMID: 19902987
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources